The estimated Net Worth of James Martell is at least $11.6 Milhão dollars as of 21 June 2011. James Martell owns over 3,100,000 units of Champions Oncology Inc stock worth over $8,350,940 and over the last 16 years James sold CSBR stock worth over $3,204,684.
James has made over 7 trades of the Champions Oncology Inc stock since 2008, according to the Form 4 filled with the SEC. Most recently James sold 3,100,000 units of CSBR stock worth $1,953,000 on 21 June 2011.
The largest trade James's ever made was selling 3,100,000 units of Champions Oncology Inc stock on 21 June 2011 worth over $1,953,000. On average, James trades about 574,617 units every 114 days since 2008. As of 21 June 2011 James still owns at least 2,051,828 units of Champions Oncology Inc stock.
You can see the complete history of James Martell stock trades at the bottom of the page.
James's mailing address filed with the SEC is 2200 WILSON BLVD. SUITE 102-316, , ARLINGTON, VA, 22201.
Over the last 21 years, insiders at Champions Oncology Inc have traded over $9,072,751 worth of Champions Oncology Inc stock and bought 42,104,566 units worth $13,657,266 . The most active insiders traders include Ventures Ix, L.P.Battery In..., Michael Maurice Brown, eSports Inc Champions. On average, Champions Oncology Inc executives and independent directors trade stock every 76 days with the average trade being worth of $2,196,294. The most recent stock trade was executed by Daniel Newman Mendelson on 12 January 2024, trading 1,000 units of CSBR stock currently worth $6,500.
champions oncology, inc. is engaged in the development of advanced technology solutions to personalize the development and use of oncology drugs. champions tumorgraft™ technology platform is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune deficient mice followed by propagation of the resulting engraftments, or tumorgrafts, in a manner that preserves the biological characteristics of the original human tumor. champions believes that these tumorgrafts, unlike cell line derived xenografts used in tradition testing, closely reflect human cancer biology and their response to drugs is predictive of clinical outcomes in cancer patients. the company offers personalized tumorgraft development, drug studies and genome sequencing as part of its personalized oncology solutions ("pos") whereby physicians can evaluate the effects of cancer drugs on their patients' tumorgrafts and understand the genetic make-up of their patient's tumor enabling them
Champions Oncology Inc executives and other stock owners filed with the SEC include: